KG
MDGL icon

Kilter Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kilter Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07K Sell
2
-1
-33% -$512 ﹤0.01% 1257
2026
Q1 		$1.57K Buy
+3
New +$1.43K ﹤0.01% 1047

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kilter Group's MDGL Position: Q2 2026 in Review

Kilter Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 33% in Q2 2026, selling an estimated $512 and leaving 2 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1257.

Kilter Group first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.57K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Kilter Group held 2 shares of Madrigal Pharmaceuticals worth $1.07K as of Q2 2026.
  • Kilter Group sold 1 Madrigal Pharmaceuticals share in Q2 2026, an estimated $512.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1257 holding.
  • Kilter Group first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Kilter Group's Madrigal Pharmaceuticals position peaked at $1.57K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.